# Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

> **NCT05636852** · PHASE2 · TERMINATED · sponsor: **GE Healthcare** · enrollment: 15 (actual)

## Conditions studied

- Parkinson Disease
- Movement Disorders

## Interventions

- **DRUG:** Altropane (123I) Injection

## Key facts

- **NCT ID:** NCT05636852
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-24
- **Primary completion:** 2024-06-08
- **Final completion:** 2024-06-08
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2025-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636852, "Altropane Dose for Imaging Patients With Suspected Parkinson's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05636852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*